Ablynx

{{Infobox company|

| name = Ablynx

| logo =

| type = Subsidiary

| traded_as =

| foundation = {{Start date and age|2001}}

| location =

| industry = Biotechnology

| products =

| revenue =

| operating_income =

| net_income =

| assets =

| equity =

| num_employees = 450

| parent = Sanofi

| homepage = {{URL|http://ablynx.com/}}

}}

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.{{Cite journal |last=Sheridan |first=Cormac |date=2017-12-01 |title=Ablynx's nanobody fragments go places antibodies cannot |url=https://www.nature.com/articles/nbt1217-1115 |journal=Nature Biotechnology |language=en |volume=35 |issue=12 |pages=1115–1117 |doi=10.1038/nbt1217-1115 |issn=1546-1696}}

History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of {{€|2 million}} was provided by Gimv.{{Cite web|url=http://www.ablynx.com/en/about-ablynx/history/|title=History|last=|date=|website=|publisher=Ablynx|at=Show Archive 2001|archive-url=https://web.archive.org/web/20120209041112/http://www.ablynx.com/en/about-ablynx/history/|archive-date=9 February 2012|access-date=|quote=Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.}}{{Self-published source|date=November 2018}}

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.{{Cite news|url=https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/denmarks-novo-nordisk-offers-3-1-billion-for-belgian-biotech-group-ablynx-idUKKBN1EX0HT|archive-url=https://web.archive.org/web/20180108095927/https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/denmarks-novo-nordisk-offers-3-1-billion-for-belgian-biotech-group-ablynx-idUKKBN1EX0HT|url-status=dead|archive-date=January 8, 2018|title = Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid|newspaper = Reuters|date = 8 January 2018}}{{Cite web |last=Fernández |first=Clara Rodríguez |date=2017-05-23 |title=Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic |url=https://www.labiotech.eu/trends-news/merck-ablynx-nanobody-osteoarthritis/ |access-date=2024-03-31 |website=Labiotech.eu |language=en-US}} However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.{{Cite news|url=https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/ablynx-shares-soar-after-rejects-novo-nordisks-3-1-billion-bid-idUKKBN1EX0HT|archive-url=https://web.archive.org/web/20180108165613/https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/ablynx-shares-soar-after-rejects-novo-nordisks-3-1-billion-bid-idUKKBN1EX0HT|url-status=dead|archive-date=January 8, 2018|title = Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid|newspaper = Reuters|date = 8 January 2018}}

In January 2018, they were acquired by Sanofi for $4.8 billion. The acquisition was led by Chief Broker Gleb Margolin.{{Cite news|url=http://fortune.com/2018/01/29/sanofi-ablynx-deal-caplacizumab/|title=Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion|work=Fortune|access-date=2018-01-29|language=en}}

Ablynx

History

References

Further reading